VivoSeq
Cardiovascular

Coronary Artery Bypass

118

Pipeline Programs↗

15

Active Trials↗

36

Companies Involved↗

Coronary Artery Bypass is a highly competitive landscape with 118 programs across 36 companies. The most active players are Roche, Hope Pharmaceuticals, Astellas. 43 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

15/100

Mech. Concentration

6/100

Completion Rate

82/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2H

Hope Pharmaceuticals

1 program

Phase 2Astellas logo

Astellas

3 programs

Phase 2I

Innogene Kalbiotech Pte. Ltd

2 programs

Phase 3C

Cosette Pharmaceuticals, Inc.

1 program

Phase 3A

Amring

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical30

Nitroglycerin

Viatris Specialty LLC

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Iloprost

BTG International Inc.

Statin

Bristol-Myers Squibb

Fentanyl

Cephalon

Phase 13

Intranasal Dexmedetomidine

Baudax Bio

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Intranasal Insulin

University Health Network, Toronto

Phase 216

Roxadustat

Astellas

Magnesium

Spherium Biomed

Nesiritide

Scios, Inc.

Sodium Nitrite

Hope Pharmaceuticals

EA-230

Radboud University Medical Center

Phase 326

Dapagliflozin

AstraZeneca

Prasugrel

Cosette Pharmaceuticals, Inc.

Propofol

Fresenius Kabi Oncology Ltd.

Tranexamic Acid

Amring

Rosuvastatin

AstraZeneca

Approved43

Dexamethasone

Aspen Global Incorporated

Ropivacaine

Fresenius Kabi Oncology Ltd.

Metformin

EMD Serono

Pantoprazole

Wyeth-Lederle Vaccines

Ketamine

Aultman Health Foundation

Analysis

Modality Breakdown

98%

Small molecule

145 of 148 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody21%Peptide1<1%

Small molecule leads; the ring shows all 148 classified programs, each share of the total. Modality classified for 100% of 149 pipeline programs.

Analysis

Trial Status

148

clinical trials

Completed80 · 54%
Unknown status36 · 24%
Terminated13 · 9%
Recruiting10 · 7%
Not yet recruiting5 · 3%
Withdrawn4 · 3%

Clinical Trials

Trial Activity

148 trials

Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery
Recruiting·UUniversity of Novi Sad·Phase 2/3·NCT06378827·100 enrolled
Thiamine Intervention and Coronary Artery Bypass Grafting
Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT06326996·52 enrolled
Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting
Recruiting·TTanta University·Phase 4·NCT05640453·70 enrolled
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT05782270·202 enrolled
Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass
Recruiting·—·N/A·NCT07248202·40 enrolled
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Recruiting·DDolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.·Phase 3·NCT07195149·1,703 enrolled
Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery
Recruiting·PPeking University First Hospital·N/A·NCT03629418·612 enrolled
Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism
Recruiting·SSeoul National University Bundang Hospital·N/A·NCT07380854·338 enrolled
Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting
Recruiting·PPeking University Third Hospital·N/A·NCT06961136·300 enrolled
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
Recruiting·—·Phase 3·NCT05852704·800 enrolled
Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients
Not yet recruiting·SShanghai Zhongshan Hospital·N/A·NCT06496165·338 enrolled
Role of Opioid Free Anaesthesia in Elderly Patients Undergoing Elective Coronary Artery Bypass Graft Surgeries With Cardiopulmonary Bypass in Enhanced Recovery After Surgeries
Not yet recruiting·—·N/A·NCT07360327·60 enrolled
Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.
Not yet recruiting·MMinia University·Phase 1·NCT06741566·150 enrolled
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
Not yet recruiting·NNanjing Medical University·N/A·NCT06730802·400 enrolled
Addition of Dexmedetomidine to Ropivacaine in Bilateral Erector Spinae Plane Block in Patients Undergoing Coronary Artery Bypass Surgery
Not yet recruiting·LLebanese American University·Phase 4·NCT06981949·110 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)